Research programme: Natural Killer receptor inhibitor - BioLineRx

Drug Profile

Research programme: Natural Killer receptor inhibitor - BioLineRx

Alternative Names: BL-9020; EDP 10; Natural cytotoxicity triggering receptor inhibitor - BioLineRx - BioLineRx; NKp46 inhibitor - BioLineRx

Latest Information Update: 19 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ben Gurion University; Hebrew University of Jerusalem
  • Developer Ben Gurion University; BioLineRx; Hebrew University of Jerusalem
  • Class Monoclonal antibodies
  • Mechanism of Action Natural cytotoxicity triggering receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 11 Mar 2015 Pharmacodynamics data from preclinical studies released by BioLineRx
  • 08 Jan 2014 BL 9020 licensed to JHL Biotech in China and South-East Asia
  • 23 Oct 2013 BL 9020 licensed to BioLineRx worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top